APLS Apellis Pharmaceuticals Inc.

14.22
+0.39  (+3%)
Previous Close 13.84
Open 13.91
Price To Book 4.09
Market Cap 800050572
Shares 56,242,571
Volume 80,052
Short Ratio
Av. Daily Volume 326,056

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due 2019.
APL-2 subcutaneous
Complement-dependent Nephropathies (CDN)
Phase 2 data presented at ASH 2018.
APL-2 subcutaneous
Auto-immune Hemolytic Anemia (AIHA)
Phase 1b trial ongoing.
APL-2 PHAROAH
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 3 enrolment to resume 2Q 2019 with completion of enrolment 1Q 2020.
APL-2
Geographic atrophy (GA) associated with age-related macular degeneration (AMD)
Phase 3 trial initiation announced June 26, 2018.
APL-2 subcutaneous
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Phase 1b update due at ASH December 2, 2018 noted normalization of mean hemoglobin to 12.2 g/dL by day 85, an increase of 4.2 g/dL from baseline.
APL-2 PADDOCK
Paroxysmal Nocturnal Hemoglobinuria

Latest News

  1. Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  2. Apellis Pharmaceuticals’ APL-2 Receives Fast Track Designation from the FDA for the Treatment of Patients with Paroxysmal Nocturnal Hemoglobinuria
  3. Apellis’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of Autoimmune Hemolytic Anemia
  4. Apellis Pharmaceuticals Appoints Thomas Lackner as Senior Vice President, Head of Europe
  5. Apellis Pharmaceuticals (APLS) in Focus: Stock Moves 7.1% Higher
  6. Apellis Pharmaceuticals to Present at the 37th Annual J.P. Morgan Healthcare Conference
  7. Is Apellis Pharmaceuticals, Inc. (APLS) A Good Stock To Buy?
  8. Apellis Pharmaceuticals’ APL-2 Receives Orphan Drug Designation from the FDA for the Treatment of C3 Glomerulopathy
  9. Apellis Pharmaceuticals Provides Update on Its Phase 3 Program for Patients with Geographic Atrophy
  10. The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials
  11. Apellis Pharmaceuticals Presents New Data from Ongoing APL-2 Phase 2 Study in Patients with Cold Agglutinin Disease and Warm Antibody Autoimmune Hemolytic Anemia at ASH
  12. Apellis Pharmaceuticals Presents Updated Data from a Clinical Study of APL-2 in Patients with Paroxysmal Nocturnal Hemoglobinuria at ASH
  13. Enable Injections inks development deals with pharma firms
  14. Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
  15. Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
  16. Apellis shares plunge after incident in two clinical trials
  17. EXCLUSIVE: Apellis CEO says company has no plans to move its HQ

SEC Filings

  1. D - Notice of Exempt Offering of Securities 10844510